Maybe, but I think opposite. Convertibles were already at discount price. So, why would they look-up return?
To me those are real short.
Their hypothesis is that A will at some point shows CNS side effects and that this will kill its further development.
For any CNS based drug, possibility of side effect is for real. Only prolonged therapy duration and large pts number can clear this issue. That is exactly what REGN is doing.
Based on drug mode of action and mechanisms, structure of the proteins and from what it is generated (CNTF is neurotropic factor), micro doses, CNS concentration, clearance, and antibody development,...I see very small chance for some serious unexpected side effects. Nonetheless, NONE for sure can tell what will be at the end.
Worth to note is that A can be develop as ON and OFF drug (3 months ON and 6 OFF, for instance), without sacrificing efficacy and sustain weight loss. I think that this will be next PIII trial designee. To repeat PII results and to expand options.
Once ~60% of the enrolled pts in current PIII passed their first 9-12 months on drug (Sept-Oct) things will become very interesting, and nerve breaking (for SHORT, normally).
Miljenko |
